Prospects for the Etiotropic Treatment of Dysferlinopathy

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Dysferlinopathies belong to a phenotypically heterogeneous group of neuromuscular diseases caused by mutations in the DYSF gene, which disrupt the expression of dysferlin protein in human skeletal muscle cells. These pathologies are of an autosomal recessive inheritance pattern, their prevalence is 1: 200000. Dysferlinopathies include diseases such as Miyoshi myopathy with primary lesion of the distal fragments of the lower extremities and limb-gridle muscular dystrophy type 2B with primary lesion of the proximal fragments of both the lower and upper limbs, also distal myopathy with anterior tibial onset (DMAT). Nowdays, there are various pathogenetic and symptomatic treatments for hereditary muscular dystrophies but there are very few registered drugs for the etiological treatment of these diseases. This review discusses the main modern methods of gene therapy that can be used to treat dysferlinopathies, such as stop-codon passing, exon skipping, overexpression of other genes, gene transfer, splicosome-mediated trans-splicing, and also describes the latest experimental studies using these methods. In conclusion, exon-skipping and trans-splicing have been identified as the most optimal approaches in the treatment of muscular dystrophies, in particular dysferlinopathies.

Full Text

Restricted Access

About the authors

Alisa V. Ivanova

Research Centre for Medical Genetics

ORCID iD: 0000-0002-8954-7330
SPIN-code: 9922-7412

Junior Researcher

Russian Federation, 115478, Moscow, Moskvorechie, 1

Svetlana A. Smirnikhina

Research Centre for Medical Genetics

ORCID iD: 0000-0002-1558-3048
SPIN-code: 6884-6170


Russian Federation, 115478, Moscow, Moskvorechie, 1

Alexander V. Lavrov

Research Centre for Medical Genetics

Author for correspondence.
ORCID iD: 0000-0003-4962-6947
SPIN-code: 4926-8347

Leading Research Scientist, MD, PhD

Russian Federation, 115478, Moscow, Moskvorechie, 1


  1. Aposhian HV. The use of DNA for gene therapy — the need, experimental approach, and implications. Perspect Biol Med. 1970;14(1):98–108. doi:
  2. Emery AE. Population frequencies of inherited neuromuscular diseases — a world survey. Neuromuscul Disord. 1991;1(1):19–29. doi:
  3. Barohn RJ, Amato AA, Griggs RC. Overview of distal myopathies: from the clinical to the molecular. Neuromuscul Disord. 1998;8(5):309–316. doi:
  4. Escolar D, O’Carroll P, Leshner R. Treatment and Management of Muscular Dystrophies. Neuromuscul Disord. 2011;343–372. doi:
  5. Aoki M. Dysferlinopathy. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds). Seattle, WA: University of Washington, Seattle; 1993.
  6. Krahn M, Wein N, Bartoli M, et al. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med. 2010;2(50):50–69. doi:
  7. Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol. 2007;64(8):1176–1182. doi:
  8. Weiler T, Bashir R, Anderson LVB, et al. Identical Mutation in Patients with Limb Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy Suggests a Role for Modifier Gene(s). Hum Mol Genet. 1999;8(5):871–877. doi:
  9. Cagliani R, Magri F, Toscano A, et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat. 2005;26(3):283. doi:
  10. Weiler T, Greenberg CR, Nylen E, et al. Limb-girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD2B and segregate with the same haplotype. Am J Hum Genet. 1996;59(4):872–878.
  11. Wang M, Guo Y, Fu Y, Jia R, Chen G. Atypical Miyoshi distal myopathy: A case report. Experimental and Therapeutic Medicine. 2016;12(5):3068–3072. doi:
  12. Urtizberea JA, Bassez G, Leturcq F, Nguyen K, Krahn M, Levy N. Dysferlinopathies. Neurol India. 2008;56(3):289–297. doi:
  13. Liewluck T, Pongpakdee S, Witoonpanich R, et al. Novel DYSF mutations in Thai patients with distal myopathy. Clin Neurol Neurosurg. 2009;111(7):613–618. doi:
  14. Illa I, Serrano-Munuera C, Gallardo E, et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol. 2001;49(1):130–134.
  15. Krahn M, Béroud C, Labelle V, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat. 2009;30(2):E345–E375. doi:
  16. Fanin M, Angelini C. Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve. 2016;54(5):821–835. doi:
  17. Magri F, Govoni A, Del Bo R, et al. Natural history and peculiar aspects in LGMD2B. XIII International Congress on Neuromuscular Diseases (ICNMD XIII). Nice, France, July 5–10, 2014.
  18. Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat. 2005;26(2):165. doi:
  19. Celik M, Ertasoglu H. Phenotypic variation in dysferlinopathy. J Neurol Sci. 2009;26(1).
  20. Kobayashi K, Izawa T, Kuwamura M, Yamate J. Dysferlin and animal models for dysferlinopathy. J Toxicol Pathol. 2012;25(2):135–147. doi:
  21. Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med. 2011;40(4,Pt2):e249–e255. doi:
  22. Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46(4):488–508. doi:
  23. Hoffman EP, Rao D, Pachman LM. Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheum Dis Clin North Am. 2002;28(4):743–757. doi:
  24. Meregalli M, Navarro C, Sitzia C, et al. Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells. FEBS J. 2013;280(23):6045–6060. doi:
  25. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, Brown RH Jr. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol. 2002;51(1):129–133. doi:
  26. Wein N, Avril A, Bartoli M, et al. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat. 2010;31(2):136–142. doi:
  27. Lee JJA, Maruyama R, Duddy W, Sakurai H, Yokota T. Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy. Mol Ther Nucleic Acids. 2018;13:596–604. doi:
  28. Lukyanenko V, Muriel JM, Bloch RJ. Coupling of excitation to Ca2+ release is modulated by dysferlin. J Physiol. 2017;595(15):5191–5207. doi:
  29. Vincent AE, Rosa HS, Alston CL, et al. Dysferlin mutations and mitochondrial dysfunction. Neuromuscul Disord. 2016;26(11):782–788. doi:
  30. Han WQ, Xia M, Xu M, et al. Lysosome fusion to the cell membrane is mediated by the dysferlin C2A domain in coronary arterial endothelial cells. J Cell Sci. 2012;125(Pt5):1225–1234. doi:
  31. Cytoplasmic Vesicles — Advances in Research and Application: 2013 Edition. P. 18.
  32. Matsuda C, Kameyama K, Tagawa K, et al. Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol. 2005;64(4):334–340. doi:
  33. Azakir BA, Di Fulvio S, Therrien C, Sinnreich M. Dysferlin interacts with tubulin and microtubules in mouse skeletal muscle. PLoS One. 2010;5(4):e10122. Published 2010 Apr 12. doi:
  34. Mariano A, Henning A, Han R. Dysferlin-deficient muscular dystrophy and innate immune activation. FEBS J. 2013;280(17):4165–4176. doi:
  35. Han R. Muscle membrane repair and inflammatory attack in dysferlinopathy. Skeletal Muscle. 2011;1(10). doi:
  36. Codding SJ, Marty N, Abdullah N, Johnson CP. Dysferlin Binds SNAREs (Soluble N-Ethylmaleimide-sensitive Factor (NSF) Attachment Protein Receptors) and Stimulates Membrane Fusion in a Calcium-sensitive Manner. J Biol Chem. 2016;291(28):14575–14584. doi:
  37. Blandin G, Beroud C, Labelle V, et al. UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene. Hum Mutat. 2012;33(3):E2317–E2331. doi:
  38. Krahn M, Béroud C, Labelle V, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat. 2009;30(2):E345–E375. doi:
  39. Takahashi T, Aoki M, Tateyama M, et al. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology. 2003;60(11):1799–1804. doi:
  40. Shin HY, Jang H, Han JH, et al. Targeted next-generation sequencing for the genetic diagnosis of dysferlinopathy. Neuromuscul Disord. 2015;25(6):502–510. doi:
  41. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418(6893):41–49. doi:
  42. [Internet]. Jain Foundation funded studies: Multipotent Adult Progenitor Cells (MAPCs). Available from:
  43. Rosales XQ, Gastier-Foster JM, Lewis S, et al. Novel diagnostic features of dysferlinopathies. Muscle Nerve. 2010;42(1):14–21. doi:
  44. Деев Р.В., Мавликеев М.О., Бозо И.Я., Пулин А.А., Еремин И.И. Генно-клеточная терапия наследственных заболеваний мышечной системы: современное состояние вопроса // Гены и клетки. — 2014. — № 4. [Deev RV, Mavlikeev MO, Yakovlev I, et al. Genno-kletochnaya terapiya nasledstvennykh zabolevaniy myshechnoy sistemy: sovremennoe sostoyanie voprosa. Geny & Kletki. 2014;9(4):6–33].
  45. Keeling KM, Xue X, Gunn G, Bedwell DM. Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet. 2014;15:371–394. doi:
  46. Aartsma-Rus A, Singh KH, Fokkema IF, et al. Therapeutic exon skipping for dysferlinopathies? [published correction appears in Eur J Hum Genet. 2010 Sep;18(9):1072-3]. Eur J Hum Genet. 2010;18(8):889–894. doi:
  47. Barthélémy F, Blouin C, Wein N, et al. Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients’ Cells. J Neuromuscul Dis. 2015;2(3):281–290. doi:
  48. Rodrigues M, Yokota T. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases. Methods Mol Biol. 2018;1828:31–55. doi:
  49. Azibani F, Brull A, Arandel L, et al. Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy. Mol Ther — Nucleic Acids. 2018;10:376–386. doi:
  50. Яковлев И.А., Деев Р.В., Соловьева В.В., и др. Пред- и посттранскрипционная модификация генетической информации в программе лечения мышечных дистрофий // Гены и клетки. — 2016. — № 11 (2). — С. 42–52. [Yakovlev IА, Deev RV, Solovyеva VV, et al. Pred-i posttranskriptsionnaya modifikatsiya geneticheskoy informatsii v programme lecheniya myshechnyh distrofiy. Geny & Kletki. 2016;11(2):42–52. (In Russ.)]
  51. Kierlin-Duncan MN, Sullenger BA. Using 5’-PTMs to repair mutant beta-globin transcripts. RNA. 2007;13(8):1317–1327. doi:
  52. Philippi S, Lorain S, Beley C, et al. Dysferlin rescue by spliceosome-mediated pre-mRNA trans-splicing targeting introns harbouring weakly defined 3′ splice sites. Hum Mol Genet. 2015;24(14):4049–4060. doi:
  53. Muruve DA, Zaiss AK. Immune Responses to Adeno-Associated Virus Vectors. Curr Gene Ther. 2005;5(3):323–331. doi:
  54. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol. 1999;73(10):8549–8558.
  55. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier MC, Bessis N. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J Clin Immunol. 2004;24(2):162–169. doi:
  56. Старостина И.Г., Соловьева В.В., Юрьева К.С., и др. Дисферлинопатии: возможности диагностики, моделирования и генно-клеточной терапии // Гены и клетки. — 2013. — № 3. — С. 61–70. [Starostina IG, Solovyeva VV, Yuryeva KS, et al. Modeling and gene therapy of dysferlinopathy. Cell Transplant Tissue Eng. 2013;8:61–70.]
  57. Escobar H, Schöwel V, Spuler S, Marg A, Izsvák Z. Full-length Dysferlin Transfer by the Hyperactive Sleeping Beauty Transposase Restores Dysferlin-deficient Muscle. Mol Ther Nucleic Acids. 2016;5(1):e277. Published 2016 Jan 19. doi:
  58. Inoue M, Wakayama Y, Kojima H, et al. Expression of myoferlin in skeletal muscles of patients with dysferlinopathy. Tohoku J Exp Med. 2006;209(2):109–116. doi:
  59. Davis DB, Delmonte AJ, Ly CT, McNally EM. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet. 2000;9(2):217–226. doi:
  60. Vainzof M, Anderson LV, McNally EM, et al. Dysferlin protein analysis in limb-girdle muscular dystrophies. Mol Neurosci. 2001;17(1):71–80. doi:
  61. Lostal W, Bartoli M, Roudaut C, et al. Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One. 2012;7(5):e38036. doi:

Supplementary files

Supplementary Files
1. Covering letter

Download (247KB)
2. Fig. 1. Dysferlin protein structure. Disferlin consists of seven C2 domains connected in series with Ca2 + binding activity, three Fer domains, two DYSF domains, one of which is located in the other, and a transmembrane T

Download (50KB)
3. Fig. 2. The main directions of SMaRT: A - 5 'trans-splicing; B - 3 'trans-splicing; B - replacement of the internal exon. The pre-trans splicing molecule (PTM) complementarily binds to the target RNA and hides the endogenous splice site, while providing its own site, which, via the spliceosome, provides the therapeutic RNA sequence

Download (128KB)



Abstract: 1277

PDF (Russian): 5

Article Metrics

Metrics Loading ...



Copyright (c) 2021 Russian academy of sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies